Anika Therapeutics (ANIK) Monovisc PMA Appeal Not Approved by FDA
Tweet Send to a FriendGet Alerts ANIK Hot Sheet
Trade ANIK Now!
Anika Therapeutics, Inc. (Nasdaq: ANIK) announced today that it has received correspondence from the Chief Scientific Officer of the Center for Devices and Radiological Health of the U.S. FDA upholding the non-approvable decision for the Monovisc PMA that was previously disclosed. The company had utilized the FDA’s appeal process to continue to discuss the Monovisc PMA with the FDA.
The company plans to schedule a meeting with the FDA as soon as possible to determine the next steps concerning the Monovisc product.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
The company plans to schedule a meeting with the FDA as soon as possible to determine the next steps concerning the Monovisc product.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Obesity Gets Some Respect (ARNA) (VVUS) (OREX)
- Actavis (ACT), Kissei Pharma Sue Sandoz, Hetero Over Rapaflo Patent
- Amarin (AMRN) Vascepa sNDA Set for Oct. 16, 2013, According to FDA
Create E-mail Alert Related Categories
FDA
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
